Ivomec Plus is an authorized prescription option indicated for the supportive care and management of various parasitic conditions. It may be used to help address internal infections, including gastrointestinal roundworms and lungworms, which can cause symptoms such as respiratory distress or gastrointestinal discomfort. The medication is also a therapeutic option for managing adult liver flukes.

Additionally, this product may be used in cases involving external parasites, such as certain species of sucking lice and mites, which are often associated with dermatological irritation. This broad therapeutic role supports the reduction of the parasite burden, promoting an improved state of well-being.

---

Quick Fact: Management for Internal and External Parasites

---

This section provides a summary of the medication's primary role in therapeutic support. Its purpose is to help manage symptoms and support recovery, not to guarantee a specific clinical outcome.

Regulatory References

1. FDA's Freedom of Information Summary for NADA 140-833

Ivomec Plus is a veterinary combination medicine whose eligibility profile is strictly defined by regulatory authorities, such as the FDA, for use in cattle. The official labeling establishes clear boundaries for who can and cannot use the product, driven by species safety and food chain residue requirements.

Eligibility Status	Population/Group	Regulatory Basis
Permitted Use	Cattle (Beef Cattle) and Breeding Stock	Authorized for the target species, including cows and bulls
Absolute Contraindication	Humans	Explicitly mandated: "NOT FOR USE IN HUMANS"
Contraindication	Other Animal Species	Use must be avoided due to severe adverse reactions, including fatalities

Use is prohibited for certain groups due to residue concerns related to the food supply. This includes Female Dairy Cattle of Breeding Age because a milk withdrawal time has not been established. Furthermore, the medicine must not be used in calves intended for processing as veal, and treated cattle are non-eligible for slaughter within 21 days of administration. Use in preruminating calves is officially not established due to insufficient data on residue withdrawal periods for this specific life stage.

Interactions with other medicines and products

The official regulatory profile for Ivomec Plus, a veterinary fixed-dose combination product, establishes specific constraints related to product handling and co-mixing, while officially stating an absence of specific drug-drug interactions.

Pharmacokinetic and Pharmacodynamic Interaction Status

Official government prescribing information, including documentation from the US Food and Drug Administration (FDA) and European regulatory bodies, does not specify any interacting medicinal product categories. Regulatory documents do not formally list any specific substances that engage in pharmacokinetic interactions, such as those related to metabolic enzymes or drug transporters, resulting in no formal classification for such effects. Furthermore, the labeling does not define any pharmacodynamic interactions or list co-administered medicines that alter the exposure (AUC or Cmax) of Ivermectin or Clorsulon. Interactions with food, alcohol, supplements, or herbal products are also not specified in the official documentation. No population-specific notes regarding interaction relevance in certain conditions are provided in the regulatory interaction sections.

Administration-Timing Restriction

The primary mandatory restriction documented in the official prescribing information concerns product mixture. Ivomec Plus is subject to a formal Major Incompatibility statement in the regulatory labeling. As a procedural consequence of this official classification, the product must not be mixed with other veterinary medicinal products at the time of administration. This requirement is mandated by regulatory authorities due to the absence of documented compatibility studies for the sterile solution.

Neuromuscular System Collapse (Ivermectin)

The component Ivermectin achieves its effect by targeting Glutamate-gated Chloride Channels ( GluCls), which are specific to invertebrate nerve and muscle cells. Ivermectin acts as an agonist, causing these channels to open irreversibly and promoting a massive influx of chloride ions ( Cl^-). This severe, sustained hyperpolarization of the post-synaptic membrane disrupts neuromuscular signal transmission, leading to functional paralysis of the parasite's motor and feeding systems.

---

Cellular Energy Metabolism Arrest (Clorsulon)

Conversely, Clorsulon acts on the specialized anaerobic glycolytic pathway within the liver fluke (Fasciola hepatica). Clorsulon functions as an inhibitor of key enzymes, including phosphoglycerate kinase (PGK) and phosphoglycerate mutase (PGM). By blocking these crucial metabolic steps, the fluke's production of ATP, its primary energy source, is rapidly diminished. This cascade leads to an acute energy deficit and subsequent loss of cellular function.

---

Dual-Mechanism Additive Strategy

The combination targets two entirely distinct and non-overlapping physiological systems: Ivermectin neutralizes the nervous system of one parasite group, while Clorsulon shuts down the energy metabolism of another. This additive approach ensures that separate parasite classes are managed by dedicated mechanisms, resulting in physiological disruption across the two targeted systems.

How to Use Ivomec Plus: Official Administration Guidelines

Ivomec Plus is administered as a sterile injectable solution for use in cattle only. Proper use is strictly defined to ensure the correct drug delivery and animal safety.

Administration Details

Feature	Official Instruction
Route of Administration	Subcutaneous injection only (under the skin).
Injection Location	Behind the shoulder. Not for intravenous or intramuscular use.
Standard Dose	1 mL per 110 lb (50 kg) of body weight, given as a single treatment.

---

Procedural Requirements

Administration requires adherence to specific procedural steps to ensure efficacy and minimize local reaction:

• Dose Calculation: The animal's weight must be accurately determined to ensure the correct volume is administered (1 mL/50 kg). A sterile 16-gauge or 17-gauge needle of 1/2" to 3/4" length must be used.
• Dividing the Dose: To reduce potential injection site reactions, doses greater than 10 mL must be divided and injected into two separate subcutaneous sites behind the shoulder.
• Temperature Management: If the product is stored or handled in temperatures of 5°C (41°F) or below, it is recommended to warm the product and the injection equipment to approximately 15°C (59°F) to improve its flow and ease of administration.
• Age and Use Restrictions: The product is suitable for all ages of cattle, including breeding bulls and cows. Do not use in female dairy cattle of breeding age or in calves being processed for veal.

Ivomec Plus: Recent Clinical Evidence

Evidence for Comprehensive Internal Parasite Control

Research examined the combination of its two active ingredients, Ivermectin and Clorsulon, in the context of internal and selected external parasite control. The primary evidence base consists mainly of Controlled Trials and Comparative Field Studies conducted on different groups of cattle, such as calves and steers, that had parasite infections.

Studies monitored responses over defined time intervals following administration. Research examined measurements of parasite burden levels using methods like post-mortem worm counts and fecal egg counting. Trials reported measured reductions in parasite burden when evaluating post-mortem worm counts in the observed animal groups. However, the studies were primarily designed to satisfy regulatory requirements, which means data for parasite species or life stages outside the immediate scope of the original focus remain insufficient.

Research Focus on Adult Liver Fluke Treatment

Research involving the Clorsulon component was evaluated in the context of the adult liver fluke (Fasciola hepatica). The evidence includes Controlled Trials and field studies focused on monitoring outcomes linked to inflammatory or irritative states caused by this specific parasite. The populations studied were cattle with Fasciola hepatica infections.

Reported findings indicate the observed effect was associated with the specific adult parasite stage, with limited effect described on other, non-adult parasite life cycles. Evidence is limited regarding the treatment's effect on immature stages of the liver fluke, and long-term effects are not fully established concerning management in areas with ongoing exposure.

Key Studies & References

1. Freedom of Information Summary for New Animal Drug Application (NADA) 140-833 (Ivermectin/Clorsulon)

Common questions about Ivomec Plus (FAQ)

---

Q: How quickly does Ivomec Plus start working after administration?

Official regulatory documents indicate that Ivomec Plus is formulated for rapid and systemic distribution throughout the animal's body. Furthermore, regulatory data supports claims of protection against reinfection for specific lungworms for up to 28 days and specific stomach worms for up to 21 days.

Q: How long do the effects of Ivomec Plus last?

According to the official product information, the treatment provides a persistent effect against certain parasite species. Regulatory documents indicate a persistent effect, providing control against reinfection for specific parasites for up to 21 to 28 days following administration.

Q: What should I do if a rare side effect occurs after using Ivomec Plus?

Official labeling instructs users to contact the manufacturer or a specified veterinary assistance line to report adverse effects, especially those that are uncommon. This procedure is mandated to help regulatory bodies monitor the safety profile of the product.

Q: Does Ivomec Plus treat both adult parasites and their larvae?

Regulatory information states that Ivomec Plus is effective against both the adult and fourth-stage larval forms of most covered roundworms. However, the treatment is indicated only for the control of adult liver flukes, and official information notes that efficacy against the immature stages of the liver fluke is not fully established.

Q: Can Ivomec Plus interact with heartworm preventatives?

Official regulatory documents do not formally list any specific drug-drug interactions with other medicinal products. However, regulatory labeling mandates that the product is not mixed with any other veterinary medicinal product at the time of administration due to incompatibility statements.

Q: Are there any known drug-herb interactions with the components of Ivomec Plus?

Official product information, including drug interaction sections, does not specify or list any interactions with herbal products. Always adhere strictly to the product's official regulatory instructions for use.

Q: Does the efficacy of Ivomec Plus change if it's stored incorrectly?

The product is required to be stored at or below 25 C (77 F) and must be protected from light. Storage outside of these mandated conditions may compromise product stability and is not recommended.

Q: Is it normal to feel a bit nauseous after taking a product containing the active ingredients in Ivomec Plus?

Ivomec Plus is a veterinary medicine and is explicitly not for human use. While the human-approved drug containing Ivermectin may list nausea as a potential side effect, this information does not apply to the veterinary product, which must be kept away from humans and non-target species.

Q: Are there any common over-the-counter supplements that shouldn't be taken with Ivomec Plus?

Official regulatory information does not specify or list any interactions with common over-the-counter supplements. Regulatory information indicates that the product must not be mixed with any other veterinary medicinal products at the time of administration.

Q: What research evidence supports the use of the two main components in Ivomec Plus?

The product was approved by regulatory bodies based on data demonstrating that it is safe and effective for the specific claims listed on the label. This evidence includes controlled trials confirming its efficacy for the treatment and control of internal and external parasites when used as directed.

Q: What are some signs that Ivomec Plus might not be working for a parasite issue?

Official product warnings note that parasite resistance to any dewormer may develop over time. The label advises that treatment be used in conjunction with parasite management practices appropriate to the area and that veterinary consultation and diagnostics be utilized to determine effectiveness.

Q: Is a withdrawal period necessary after using Ivomec Plus?

Yes, a strict withdrawal period is mandated by regulatory bodies to prevent drug residues from entering the food supply. Treated cattle must not be slaughtered for use in food within 21 days following the administration of Ivomec Plus.

Q: Is it true that some people use Ivomec Plus for purposes other than the main listed use?

The official label carries an explicit mandate: NOT FOR USE IN HUMANS. The product is strictly a veterinary medicine approved only for use in cattle and is prohibited in non-target species due to the risk of severe toxicity.

Q: Are there any age restrictions for using Ivomec Plus in young animals?

The product is suitable for all ages of cattle, including breeding bulls and cows. However, the label contains restrictions for certain life stages, stating that the product is prohibited in calves being processed for veal, and a withdrawal period has not been established for pre-ruminating calves.

Q: What happens in the body that causes the side effects associated with Ivomec Plus?

The label notes that common and expected reactions, such as transient discomfort and soft-tissue swelling, are observed following the subcutaneous route of administration. However, the official documentation does not detail the underlying biological mechanism that causes this specific local tissue reaction.

Q: Can Ivomec Plus be used in combination with vaccines, and is there a risk?

The official label specifies that different injection sites should be utilized for other parenteral products. Furthermore, the product must not be mixed with any other veterinary product at the time of administration due to major incompatibility statements.

Q: What are the visual characteristics of Ivomec Plus (color, consistency)?

Ivomec Plus is officially described as a ready-to-use sterile solution for injection. The product’s appearance is generally clear or yellowish, which is consistent with the non-aqueous solvents used in its formulation.

Q: How is resistance to Ivomec Plus managed or prevented in large-scale use?

Official labeling advises that treatment should be used in conjunction with parasite management practices appropriate to the local area and the animals being treated. This comprehensive approach is recommended to slow the development of parasite resistance to the product.

Q: What happens if a smaller amount of Ivomec Plus is administered than recommended?

The label contains warnings against underdosing. Administering less than the recommended volume may result in ineffective treatment and encourage the development of parasite resistance, potentially reducing the product's long-term effectiveness.

Q: Can Ivomec Plus be used in conjunction with topical flea/tick treatments?

Official regulatory information does not formally list any specific drug-drug interactions with other medicinal products. However, the regulatory information indicates that the product must not be mixed with other veterinary medicinal products at the time of administration.

Q: What specific species are included in the 'Plus' coverage of Ivomec Plus?

The 'Plus' component, Clorsulon, is primarily responsible for targeting the adult liver fluke (Fasciola hepatica). The official label provides a comprehensive list of all covered parasites, including various species of gastrointestinal roundworms, lungworms, cattle grubs, sucking lice, and mange mites.

Q: How can I tell the difference between a mild side effect and a serious reaction to Ivomec Plus?

The label describes common reactions as transitory discomfort and soft-tissue swelling at the injection site, which typically resolve without treatment. Serious reactions may include outcomes like bloat or paralysis, which can occur due to host-parasite reactions when cattle grub larvae die in critical areas. The label directs users to contact the manufacturer or veterinary assistance line if a serious adverse reaction is suspected.

Q: Are there any dietary restrictions needed when using Ivomec Plus?

Official regulatory information, including the interaction sections, does not specify or list any interactions with food. There are no dietary restrictions specified in the administration guidelines related to the use of Ivomec Plus.

Q: Does Ivomec Plus have any known neurotoxic effects?

The margin of safety for the Ivermectin component is attributed, in part, to the fact that mammals have different target channels than parasites and Ivermectin does not readily cross the blood-brain barrier at the recommended dose. However, fatal reactions have been documented when the product is administered to non-target species.

Storage and Disposal of Ivomec Plus Injection

Storage of Ivomec Plus is strictly defined to maintain product stability. The injection must be stored at or below 25°C (77°F) and should be protected from light and kept in its closed original container.

Container Rule	Requirement
50 mL bottle	Use within 6 months of first puncture; do not exceed 12 punctures.
Large needles	Discard remaining product immediately if a needle larger than 16-gauge is used.

For child safety, the product must be kept out of the reach of children. Disposal instructions mandate that unused product and empty containers be disposed of in an approved landfill or by incineration. Environmental regulations prohibit contaminating water with the product and restrict feedlot runoff from entering natural water sources.